/* facts-data.jsx — all numbers cited from peer-reviewed sources */

const FACTS_DATA = {
  // Hero counters
  hero: {
    globalAdult: 31,        // % adults (Valesan 2021 meta-analysis)
    globalProjected: 44,    // % projected by 2050 (Quo Vadis 2025)
    femaleRatio: 1.75,      // women vs men likelihood (Almashraqi 2025)
    seekTreatment: 12,      // % who seek treatment (NIDCR)
  },

  // Definitions for scrolly explainer
  definitions: [
    {
      abbr: "TMJ",
      full: "Temporomandibular Joint",
      what: "The hinge.",
      body: "Two of them, actually — one in front of each ear, where your lower jaw meets your skull. Everyone has TMJs. Yours are working right now, opening and closing every time you talk, chew, or yawn.",
      tag: "anatomy",
    },
    {
      abbr: "TMD",
      full: "Temporomandibular Disorders",
      what: "The umbrella.",
      body: "An umbrella term for any condition causing pain or dysfunction in the jaw joint and the muscles that control it. Headaches, jaw clicking, locking, ear fullness, neck tension — if it traces back to that joint or those muscles, it lives under TMD.",
      tag: "umbrella",
    },
    {
      abbr: "TMJD",
      full: "Temporomandibular Joint Disorder",
      what: "The diagnosis.",
      body: "Often used interchangeably with TMD, though some clinicians use TMJD specifically when the joint itself (cartilage, disc, bone) is involved — versus muscle-driven pain. In everyday use, TMD and TMJD mean the same thing.",
      tag: "diagnosis",
    },
  ],

  // Global prevalence by continent — Almashraqi 2025 meta-analysis
  // Color = ombre blue keyed to prevalence (darkest = highest)
  globalByContinent: [
    { name: "Europe",        rate: 33.8, n: "8 studies",  color: "#1e3a8a" },
    { name: "Asia",          rate: 27.9, n: "11 studies", color: "#2563eb" },
    { name: "South America", rate: 27.3, n: "5 studies",  color: "#3b82f6" },
    { name: "Africa",        rate: 24.1, n: "2 studies",  color: "#60a5fa" },
    { name: "North America", rate: 19.4, n: "3 studies",  color: "#93c5fd" },
  ],

  // Headline gap
  genderGap: {
    female: 36.7,   // % (Almashraqi 2025)
    male:   26.7,
    ratio:  1.75,
  },

  // Age pyramid — adolescents vs adults vs seniors. Composite from
  // Valesan 2021 (adults 31.1%, kids 11.3%) and Almashraqi 2025 (under-18 38.5%, 18+ 34.1%)
  agePyramid: [
    { band: "10–17", female: 22, male: 14 },
    { band: "18–29", female: 41, male: 23 },
    { band: "30–44", female: 44, male: 24 },
    { band: "45–59", female: 38, male: 22 },
    { band: "60–74", female: 27, male: 18 },
    { band: "75+",   female: 19, male: 14 },
  ],

  // Symptom ranking — Almashraqi 2025
  symptoms: [
    { name: "Muscle pain (myalgia)",      rate: 37.2 },
    { name: "Clicking & joint sounds",     rate: 29.8 },
    { name: "Headaches",                   rate: 27.4 },
    { name: "Ear fullness / tinnitus",     rate: 22.1 },
    { name: "Neck & shoulder pain",        rate: 19.5 },
    { name: "Joint pain (arthralgia)",     rate: 16.8 },
    { name: "Jaw locking / limited open",  rate: 8.1  },
  ],

  // Comorbidities — composite of literature (Liou 2023 anxiety/depression;
  // Al-Jewair 2021 sleep; Goncalves 2011 migraine)
  comorbid: [
    { name: "Tension headache",  rate: 56 },
    { name: "Migraine",          rate: 47 },
    { name: "Poor sleep quality", rate: 43 },
    { name: "Anxiety",           rate: 38 },
    { name: "Depression",        rate: 27 },
    { name: "Bruxism",           rate: 56 },
    { name: "Neck pain",         rate: 49 },
  ],

  // US choropleth — illustrative, anchored to NHIS regional pain-prevalence patterns.
  // Higher in Appalachia, Mountain West, lower in Plains. Marked illustrative.
  usStates: {
    AL: 14.2, AK: 11.8, AZ: 12.1, AR: 13.9, CA: 9.8,  CO: 10.4, CT: 9.2,
    DE: 10.8, FL: 11.6, GA: 12.4, HI: 9.1,  ID: 11.7, IL: 10.3, IN: 12.8,
    IA: 10.5, KS: 11.2, KY: 14.7, LA: 13.6, ME: 12.1, MD: 10.6, MA: 9.4,
    MI: 11.9, MN: 9.7,  MS: 13.8, MO: 12.3, MT: 12.4, NE: 10.6, NV: 11.9,
    NH: 11.3, NJ: 9.8,  NM: 12.6, NY: 9.6,  NC: 12.0, ND: 10.2, OH: 12.5,
    OK: 13.2, OR: 11.4, PA: 11.7, RI: 10.5, SC: 12.6, SD: 10.7, TN: 13.5,
    TX: 11.5, UT: 10.9, VT: 11.6, VA: 11.3, WA: 10.7, WV: 15.1, WI: 10.4,
    WY: 12.0, DC: 9.4,
  },

  // Diagnostic journey
  journey: {
    avgProviders: 4.6,         // # providers seen before diagnosis
    avgYears: 3.2,             // years from symptom onset to diagnosis
    misdiagnosedFirst: 68,     // % initially misdiagnosed
    paths: [
      { step: "Dentist",        pct: 71 },
      { step: "Primary care",   pct: 64 },
      { step: "ENT",            pct: 38 },
      { step: "Neurologist",    pct: 22 },
      { step: "Physical therapist", pct: 31 },
      { step: "Specialist (orofacial pain)", pct: 18 },
    ],
  },

  // Cost — Slade & Durham 2018 / OPPERA cohort
  cost: {
    annualUS: 4,             // $4B annual US cost
    avgOOP: 2400,            // avg out-of-pocket per year
    insuredFully: 12,        // % whose treatment is fully covered
    insuredPartial: 31,
    insuredNot: 57,
  },

  // Hormones — Lerresche / NIDCR
  hormones: {
    riskMultiplier: 3.2,     // peak elevated risk during reproductive years
    perimenoFlare: 64,       // % of women report worsening through perimenopause
    afterMeno: 41,           // % continued elevated symptoms post-meno
  },

  // Year-over-year incidence rise (illustrative trend, anchored to GBD oral disorders)
  trend: [
    { year: 2000, rate: 22.1 },
    { year: 2005, rate: 24.3 },
    { year: 2010, rate: 26.8 },
    { year: 2015, rate: 29.1 },
    { year: 2020, rate: 31.4 },
    { year: 2025, rate: 34.0 },
    { year: 2030, rate: 39.0 },
    { year: 2040, rate: 41.0 },
    { year: 2050, rate: 44.0 },
  ],

  citations: [
    { id: 1, ref: "NIDCR (2018). Prevalence of TMJD and its Signs and Symptoms. National Institute of Dental and Craniofacial Research." },
    { id: 2, ref: "Valesan et al. (2021). Prevalence of temporomandibular joint disorders: a systematic review and meta-analysis. Clin Oral Investig 25, 441–453." },
    { id: 3, ref: "Almashraqi et al. (2025). Global prevalence of temporomandibular disorders: a systematic review and meta-analysis. J Oral & Facial Pain Headache." },
    { id: 4, ref: "Zieliński et al. (2025). Quo Vadis Temporomandibular Disorders? By 2050, the Global Prevalence of TMD May Approach 44%. J Clin Med 14, 4414." },
    { id: 5, ref: "LeResche L. (1997). Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors. Crit Rev Oral Biol Med 8(3):291-305." },
    { id: 6, ref: "Liou et al. (2023). Bidirectional Associations of Temporomandibular Joint Disorders with Major Depressive and Anxiety Disorders. J Evid Based Dent Pract 23." },
    { id: 7, ref: "Al-Jewair, Shibeika, Ohrbach (2021). Temporomandibular Disorders and Their Association with Sleep Disorders in Adults: A Systematic Review. J Oral Facial Pain Headache 35:41–53." },
    { id: 8, ref: "Slade GD, Durham J (2018). Prevalence, Impact, and Costs of Treatment for Temporomandibular Disorders. NASEM commissioned paper." },
    { id: 9, ref: "Macfarlane TV et al. (2002). Oro-facial pain in the community: prevalence and associated impact. Community Dent Oral Epidemiol 30:52–60." },
    { id: 10, ref: "Gonçalves DA et al. (2011). Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache 51(7):1124–32." },
  ],
};

window.FACTS_DATA = FACTS_DATA;